News Related to Generalized Anxiety Disorder

Related coverage linked through entity extraction aliases.

Compass Pathways' psilocybin data lifts psychedelic drug stocks

Apr 20, 2026

Compass Pathways reported positive late-stage COMP360 psilocybin data in treatment-resistant depression and plans FDA talks ahead of a filing between October and December. The update lifted shares across several psychedelics developers.

Single Doses of Psychedelics Show Lasting Relief for OCD and Anxiety in Clinical Trials

Mar 06, 2026

New clinical trials show single doses of psilocybin and LSD produce significant, lasting reductions in OCD and generalized anxiety disorder symptoms for up to 12 weeks, marking a potential shift from daily medication regimens.